RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I think that the Varney paper that someone posted a link to here supports your thinking. Leaving aside the details (since I only glossed the ms), Varney focused on the high incidence of SA in patients being treated with opioids. I think this outlines how Varney envisions the partnership bundle. It also provides something of a hedge if the SA study outcome is muddy (likely given the heterogeneity of the subject sample). If there is anything at all in the data, they may seek to negotiate a clinical trial in which SA in post-op, opioid-medicated patients is treated using ampakines. In this group, SA events are likely common, yet not life-threatening. Testing ampakines on this patient population would finesse some of the safety issues that present challenges for an RD study, but will butress efficacy data.

So yes, probably things are on hold until the SA trial is completed. Weeks? Months?